Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Gene Silencing/Gene Editing » Roberto Guerciolini

Roberto Guerciolini

Nov 08, 2007
Premium
Dicerna, an RNAi drug startup based in Boston (see related story, this issue), has appointed Roberto Guerciolini as senior vice president of pharmaceutical development.
 
Guerciolini, who is also a co-founder of Dicerna, was previously the senior vice president of development and chief medical officer of Sirna Therapeutics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Not Counting These

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Caputo on Leave

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

The Timing of a Vaccine

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

Nature Papers Report on Mass Spec Repository, Tumor Signaling Maps, Viking Genetics

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.

Oct
28
Featured Webinar

How Low Can You Go? Reduce Breeding Costs with an Optimized Genotyping and Analysis Strategy

Sponsored by
NRGene

Molecular breeding methods such as genomic selection and genome-wide association studies often require high-density genotypic data from many samples, but the cost and complexity of genotyping at this scale may be prohibitive.

What's Popular?

In Gene Silencing/Gene Editing

  1. JumpCode Genomics Emerges From Stealth Mode With CRISPR-Based Library Prep Kits

    Premium

  2. Startup Stitch Bio Bets on CRISPR Tech to Render Cancer Cells With Gene Fusions Druggable

    Premium

  3. CRISPR-Chip Maker Cardea Bio Raises $7.5M in First Close of Series A2 Financing Round

  4. Patent Board Rules Broad Institute First With Functioning CRISPR System in Eukaryotic Cells

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.